Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Total Current Liabilities: 2019-2024

Historic Total Current Liabilities for Eton Pharmaceuticals (ETON) over the last 6 years, with Dec 2024 value amounting to $19.9 million.

  • Eton Pharmaceuticals' Total Current Liabilities rose 123.89% to $44.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.2 million, marking a year-over-year increase of 123.89%. This contributed to the annual value of $19.9 million for FY2024, which is 22.82% up from last year.
  • Eton Pharmaceuticals' Total Current Liabilities amounted to $19.9 million in FY2024, which was up 22.82% from $16.2 million recorded in FY2023.
  • Over the past 5 years, Eton Pharmaceuticals' Total Current Liabilities peaked at $19.9 million during FY2024, and registered a low of $3.8 million during FY2020.
  • In the last 3 years, Eton Pharmaceuticals' Total Current Liabilities had a median value of $16.2 million in 2023 and averaged $14.2 million.
  • Data for Eton Pharmaceuticals' Total Current Liabilities shows a peak YoY spiked of 151.37% (in 2023) over the last 5 years.
  • Over the past 5 years, Eton Pharmaceuticals' Total Current Liabilities (Yearly) stood at $3.8 million in 2020, then climbed by 20.14% to $4.6 million in 2021, then soared by 41.75% to $6.5 million in 2022, then skyrocketed by 151.37% to $16.2 million in 2023, then increased by 22.82% to $19.9 million in 2024.